Clinical Trials Logo

Colitis clinical trials

View clinical trials related to Colitis.

Filter by:

NCT ID: NCT05218850 Recruiting - Ulcerative Colitis Clinical Trials

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

Start date: June 29, 2022
Phase: Phase 1
Study type: Interventional

Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.

NCT ID: NCT05213234 Recruiting - Ulcerative Colitis Clinical Trials

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels. All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) month 3, at the completion of first arm (Condition 1), and 3) month 6, after completion of the second arm (Condition 2). During these study time points, participants will be asked to complete questionnaires, track their 5-ASA medication usage, provide a stool sample, blood draw, urine test, wear a watch to measure sleep patterns, and complete a flexible sigmoidoscopy.

NCT ID: NCT05205603 Recruiting - Ulcerative Colitis Clinical Trials

Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Start date: January 15, 2022
Phase: Phase 4
Study type: Interventional

Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence of ulcerative colitis. The role of 5-ASA in promoting a higher rate of endocsopic remission is unclear. We aim to evaluate the efficacy of combination of 5-ASA and biologics in treating ulcerative colitis.

NCT ID: NCT05194007 Recruiting - Clinical trials for Ulcerative Colitis Chronic Moderate

Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease

Start date: February 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a pilot, prospective, double-blinded, two-arm, randomized controlled trial of the efficacy of Frondanol in comparison to placebo in decreasing bowel inflammation in patients with a clinical diagnosis of inflammatory bowel disease who are in remission and on standard of care treatment.

NCT ID: NCT05189327 Recruiting - Clinical trials for Ulcerative Colitis Chronic

Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan

NUCaCD
Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

The NUCaCD study aims to develop a reliable registry of patients suffering inflammatory bowel diseases in the Republic of Kazakhstan.

NCT ID: NCT05186623 Recruiting - Ulcerative Colitis Clinical Trials

Prediction Model for Response to Biologics and Small Molecular Agent for UC

Start date: February 5, 2022
Phase:
Study type: Observational [Patient Registry]

This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.

NCT ID: NCT05181137 Recruiting - Ulcerative Colitis Clinical Trials

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Start date: November 5, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

NCT ID: NCT05176366 Recruiting - Ulcerative Colitis Clinical Trials

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

Protocol Summary - Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative colitis. - Short Title: ExoFlo for ulcerative colitis - Phase: 1 - Methodology: Open label - Study Duration: 24 months - Subject Participation: 58 weeks - Single or Multi-Site: Multi-Site

NCT ID: NCT05118919 Recruiting - Ulcerative Colitis Clinical Trials

A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

Start date: February 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.

NCT ID: NCT05076175 Recruiting - Colitis, Ulcerative Clinical Trials

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Start date: May 30, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.